Bristol-Myers Squibb Launches an Online Resource for Patients with Chronic
Myeloid Leukaemia in 15 European Countries
PARIS, December 7, 2012
PARIS, December 7, 2012 /PRNewswire/ --
My CML Life Online Resource Centre Empowers and Guides Patients with CML
Through Different Stages of Their Journey
Bristol-Myers Squibb Company (NYSE:BMY) today announced the introduction of
"My CML Life", a disease awareness website for patients with chronic myeloid
leukaemia (CML). In recognition of the need to raise awareness of this rare
cancer, Bristol-Myers Squibb launched the "My CML Life" website to provide
patients in Europe with easy-to-understand medical information and tools that
offer support through various stages of their journey with CML.
"We are excited to bring this resource to patients and their caregivers in
Europe," said Estelle Vester-Blockland, Executive Medical Director Oncology
for Bristol-Myers Squibb. "Bristol-Myers Squibb will be providing this
resource to patients in 15 countries across Europe, offering them support to
manage and cope with their disease, and empower them to have a more informed
dialogue with their doctor".
The educational content featured on the "My CML Life" website was developed by
Bristol-Myers Squibb in close consultation withtheir advisory committee.
Comprising CML medical experts who verified the scientific information and
patient advocates who ensured that the patients' needs were taken into
account, the committee worked in collaboration with BMS to provide insight and
feedback on content, development and structure.
"We were looking to take a patient-oriented approach to explain to the
patient, in a friendly way, the most important things when living with CML,"
said Dr Javier López Jiménez, head of the clinical department at the Hospital
Ramón y Cajal in Madrid and member of the "My CML Life" website advisory
committee. "I think that the website can be a big help for the patient
because, when the patient is quiet at home, he can look at it and know better
the side effects and how to manage them".
The "My CML Life" website provides patients with information on CML symptoms
and diagnosis, an overview of available treatment options, and what to expect
at treatment initiation and monitoring. The site also offers easy-to-use
practical tools and services for patients. These include key questions for
patients to ask their doctor during follow-up visits and treatment, adverse
event diaries to help monitor their progress, and disease management tips to
support them in their daily journey in CML. Links to other useful resources,
including a list of patient advocacy groups,are also available for patients
to access information from leading CML experts.
For more information about "My CML Life"
The website has recently been launched in Spain and France and will be rolled
out in 13 other countries across Europe including Austria, Belgium, Denmark,
Greece, Ireland, the Netherlands, Norway, Poland, Portugal, Romania, Sweden,
Switzerland and the U.K.
Please visit http://www.mycmllife.eu/fr/ and http://www.mycmllife.eu/es/
About Chronic Myeloid Leukaemia
CML is a slow-growing type of leukaemia in which the body produces an
uncontrolled number of abnormal white blood cells. ^[ ^1 ^] CML accounts for
15% of all leukaemias. ^[ ^2 ^] In Europe, the incidence is estimated at 10 to
15 cases per 1,000,000 people. ^[ ^3 ^]
CML occurs when pieces of two different chromosomes (9 and 22) break off and
attach to each other. The new chromosome is called the Philadelphia-positive
chromosome, which contains an abnormal gene called BCR-ABL that signals cells
to make too many white blood cells. There is no known cause for the genetic
change that causes CML.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases.
1. Macmillan Cancer Support. Leukaemia Overview. Available at:
. Last accessed April 2012.
2. National Comprehensive Cancer Network (NCCN). Chronic Myelogenous Leukemia
- Clinical Practice Guidelines in Oncology - v.1.2007.
3 . Baccarani, M et al . Annals Oncol. 2012:23 (Suppl 7):vii72-vii77.
Contact: Media Contact: Astrid Harmel, +33-1-58-83-61-49,
Press spacebar to pause and continue. Press esc to stop.